Publications
Number
Publication
Language
Pharma Location Switzerland
MFN: Looking forward
MFN is already affecting Switzerland: companies are delaying or pausing launches. Low Swiss prices remain a strategic vulnerability beyond 2029, so Switzerland should prepare now.
MFN: Looking forward
